developed a type of M1‐like macrophages‐derived exosome‐mimetic nanovesicles (M1NVs), which could target tumor due to the enhanced expression of leukocyte‐derived adhesion molecules (e.g., lymphocyte function‐associated antigen 1, LFA‐1) on M1NVs, and efficiently polarize M2‐like TAMs into M1 phenotype.[127] The M1NVs increased M1‐related makers (including CD86, IL‐6, TNF‐α, and iNOS), up‐regulated M1‐related miRNAs (including miR‐155, miR‐125, and miR‐21) and down‐regulated M2‐related miRNAs (miR‐34a, let‐7c, and let‐7f) compared to the unstimulated M0NVs. This evidence concerns the gene CD86 and neoplasm.